Latest & greatest articles for oxcarbazepine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on oxcarbazepine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on oxcarbazepine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for oxcarbazepine

1. Oxcarbazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. (PubMed)

Oxcarbazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. This is an updated version of the Cochrane Review previously published in 2013. This review is one in a series of Cochrane Reviews investigating pair-wise monotherapy comparisons.Epilepsy is a common neurological condition in which abnormal electrical discharges from the brain cause recurrent unprovoked seizures. It is believed that with effective drug treatment, up to 70% of individuals with active (...) epilepsy have the potential to become seizure-free and go into long-term remission shortly after starting drug therapy with a single antiepileptic drug in monotherapy.Worldwide, phenytoin is a commonly used antiepileptic drug. It is important to know how newer drugs, such as oxcarbazepine, compare with commonly used standard treatments.To review the time to treatment failure, remission and first seizure with oxcarbazepine compared to phenytoin, when used as monotherapy in people with focal onset

2018 Cochrane

2. Oxcarbazepine

Oxcarbazepine Top results for oxcarbazepine - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for oxcarbazepine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

3. Oxcarbazepine for neuropathic pain. (PubMed)

Oxcarbazepine for neuropathic pain. Several anticonvulsant drugs are used in the management of neuropathic pain. Oxcarbazepine is an anticonvulsant drug closely related to carbamazepine. Oxcarbazepine has been reported to be efficacious in the treatment of neuropathic pain, but evidence from randomised controlled trials (RCTs) is conflicting. Oxcarbazepine is reportedly better tolerated than carbamazepine. This is the first update of a review published in 2013.To assess the benefits and harms (...) of oxcarbazepine for different types of neuropathic pain.On 21 November 2016, we searched the Cochrane Neuromuscular Specialised Register, CENTRAL, MEDLINE and Embase. We searched the Chinese Biomedical Retrieval System (January 1978 to November 2016). We searched the US National Institutes of Health (NIH) databases and the World Health Organization (WHO) International Clinical Trials Registry Platform for ongoing trials in January 2017, and we wrote to the companies who make oxcarbazepine and to pain experts

Full Text available with Trip Pro

2017 Cochrane

4. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine Clinical Pharmacogenetics Implementation Consortium Guideline forHLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update ElizabethJ.Phillips 1 ,ChonlaphatSukasem 2,3 ,MichelleWhirl-Carrillo 4 ,DanielJ.M€ uller 5,6 , HenryM.Dunnenberger 7 ,WasunChantratita 8,9 ,BarryGoldspiel 10 ,Yuan-TsongChen 11,12 , BruceC.Carleton 13 ,AlfredL.GeorgeJr. 14 (...) supporting these associations and provide recommendationsforcarbamazepineandoxcarbazepineusebased onHLAgenotypes. Human leukocyte antigen (HLA) genetic variation is implicated in the development of speci?c cutaneous adverse reactions to aro- matic anticonvulsants. The purpose of this guideline is to inter- pret HLA-B*15:02 and HLA-A*31:01 genotyping results to guide the use of carbamazepine and oxcarbazepine. Detailed guidelines regarding the selection of alternative therapies, when to conduct genotype

2017 Clinical Pharmacogenetics Implementation Consortium

5. WITHDRAWN: Oxcarbazepine add-on for drug-resistant partial epilepsy. (PubMed)

WITHDRAWN: Oxcarbazepine add-on for drug-resistant partial epilepsy. Most people with epilepsy have a good prognosis and their seizures can be well controlled with the use of a single antiepileptic drug, but up to 30% develop refractory epilepsy, especially those with partial seizures. In this review we summarize the current evidence regarding oxcarbazepine when used as an add-on treatment for drug-resistant partial epilepsy.To evaluate the effects of oxcarbazepine when used as an add (...) -on treatment for drug-resistant partial epilepsy.We searched the Cochrane Epilepsy Group's Specialized Register (28 March 2006), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 1, 2006), MEDLINE (1966 to March 2006). No language restrictions were imposed. We checked the reference lists of retrieved studies for additional reports of relevant studies. We also contacted Novartis (manufacturers of oxcarbazepine) and experts in the field.Randomized, placebo-controlled

Full Text available with Trip Pro

2016 Cochrane

6. Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine

Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized (...) , double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine Zaccara G, Giovannelli F, Maratea D, Fadda V, Verrotti A CRD summary The authors concluded that antiepileptic drugs may cause neurological adverse events in patients with drug resistant epilepsy, which can limit their use and impair treatment success; higher doses of oxcarbazepine were associated with more frequent adverse events. The evidence had several limitations and the findings were not weighed against drug

Full Text available with Trip Pro

2013 DARE.

7. Oxcarbazepine versus Other Anticonvulsants for the Treatment of Epilepsy: Clinical Effectiveness and Safety

Oxcarbazepine versus Other Anticonvulsants for the Treatment of Epilepsy: Clinical Effectiveness and Safety Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time (...) for the purposes of research or private study only. It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Oxcarbazepine versus

2012 Canadian Agency for Drugs and Technologies in Health - Rapid Review

8. Oxcarbazepine for Non-Epilepsy Indications: Clinical Effectiveness and Safety

Oxcarbazepine for Non-Epilepsy Indications: Clinical Effectiveness and Safety Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should (...) study only. It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Oxcarbazepine for Non-Epilepsy Indications

2012 Canadian Agency for Drugs and Technologies in Health - Rapid Review

9. Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions

Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions Risk of serious skin-related adverse drug reactions, including Stevens-Johnson syndrome, occurring with carbamazepine may be increased in the presence of the HLA (...) -A*3101 allele in patients of European descent or Japanese origin. Published 11 December 2014 From: Therapeutic area: , Article date: December 2012 Carbamazepine (Tegretol) is an antiepileptic drug that is indicated for the treatment of generalised tonic clonic seizures. Carbamazepine is also licensed to treat the paroxysmal pain of trigeminal neuralgia and for the prophylaxis of manic-depressive psychosis in patients unresponsive to lithium therapy. Oxcarbazepine (Trileptal) is indicated

2012 MHRA Drug Safety Update

10. New users of the anticonvulsants gabapentin, lamotrigine, oxcarbazepine or tiagabine are at increased risk of suicidal acts compared with new users of topiramate

New users of the anticonvulsants gabapentin, lamotrigine, oxcarbazepine or tiagabine are at increased risk of suicidal acts compared with new users of topiramate New users of the anticonvulsants gabapentin, lamotrigine, oxcarbazepine or tiagabine are at increased risk of suicidal acts compared with new users of topiramate | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser (...) , oxcarbazepine or tiagabine are at increased risk of suicidal acts compared with new users of topiramate Article Text Aetiology New users of the anticonvulsants gabapentin, lamotrigine, oxcarbazepine or tiagabine are at increased risk of suicidal acts compared with new users of topiramate Statistics from Altmetric.com Question Question Is new use of anticonvulsants associated with an increased risk of suicidal acts or violent death? People 297 620 people aged over 15 years of age who began taking

2010 Evidence-Based Mental Health

11. Oxcarbazepine for refractory epilepsy: systematic review of the literature

Oxcarbazepine for refractory epilepsy: systematic review of the literature Oxcarbazepine for refractory epilepsy: systematic review of the literature Oxcarbazepine for refractory epilepsy: systematic review of the literature Saconato H, do Prado GF, dos Santos Puga ME, Atallah AN CRD summary The review found that oxcarbazepine was effective as an alternative treatment for refractory partial or generalised epilepsy in children and adults. Given the limited evidence base, limitations (...) in the review process and methodological flaws in the included studies, the authors' conclusion should be treated with caution. Authors' objectives To evaluate the effectiveness of oxcarbazepine for refractory partial or generalised epilepsy. Searching PubMed (1966 to July 2008), EMBASE, LILACS and Cochrane Central Register of Controlled Trials (CENTRAL) (2008) were searched for relevant studies in any language; search terms were reported. Reference lists from retrieved studies and relevant reviews were

Full Text available with Trip Pro

2009 DARE.

12. Oxcarbazepine is no more effective than placebo for reducing manic symptoms of bipolar I disorder in children and adolescents

Oxcarbazepine is no more effective than placebo for reducing manic symptoms of bipolar I disorder in children and adolescents Oxcarbazepine is no more effective than placebo for reducing manic symptoms of bipolar I disorder in children and adolescents | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Oxcarbazepine is no more effective than placebo for reducing manic symptoms of bipolar I disorder in children and adolescents Article Text

2008 Evidence-Based Mental Health

13. Oxcarbazepine in the maintenance treatment of bipolar disorder. (PubMed)

Oxcarbazepine in the maintenance treatment of bipolar disorder. Some studies have suggested that oxcarbazepine has a role in preventing episode recurrence in bipolar affective disorder. This review attempted to investigate the existing evidence from randomised controlled trials for its use in the maintenance treatment of this illness.To review the efficacy of oxcarbazepine, relative to placebo and other agents, in the prevention of affective episodes of bipolar affective disorder. The efficacy (...) of oxcarbazepine was considered in terms of episode recurrence, general and social functioning. Adverse effects, overall acceptability to participants and mortality were also considered.CCDANCTR-Studies and CCDANCTR-References were searched on 7/11/2007. Medline, CENTRAL, EMBASE and PsycINFO were searched in March 2007. Specialist journals and conference proceedings were handsearched. Reference lists of relevant papers and major textbooks of affective disorder were checked. Authors, experts in the field

2008 Cochrane

14. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial

The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 NHS Economic Evaluation Database.

15. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. (PubMed)

The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Carbamazepine is widely accepted as a drug of first choice for patients with partial onset seizures. Several newer drugs possess efficacy against these seizure types but previous randomised controlled trials have failed to inform a choice between these drugs. We aimed to assess efficacy with regards to longer-term (...) outcomes, quality of life, and health economic outcomes.SANAD was an unblinded randomised controlled trial in hospital-based outpatient clinics in the UK. Arm A recruited 1721 patients for whom carbamazepine was deemed to be standard treatment, and they were randomly assigned to receive carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate. Primary outcomes were time to treatment failure, and time to 12-months remission, and assessment was by both intention to treat and per protocol

Full Text available with Trip Pro

2007 Lancet Controlled trial quality: predicted high

16. Oxcarbazepine versus phenytoin monotherapy for epilepsy. (PubMed)

Oxcarbazepine versus phenytoin monotherapy for epilepsy. Worldwide, phenytoin is a commonly used antiepileptic drug. Oxcarbazepine is one of the newer antiepileptic drugs and has similar chemical properties to its parent compound carbamazepine. For the new drugs such as oxcarbazepine, it is important to know how they compare with standard treatments.To review the best evidence comparing oxcarbazepine and phenytoin when used as monotherapy in patients with epilepsy.We searched the Cochrane (...) a comparison of oxcarbazepine monotherapy with phenytoin monotherapy.This was an individual patient data review. Two review authors independently assessed trial quality and extracted data. Study authors were contacted for additional information. Outcomes were (a) time on allocated treatment; (b) time to achieve 6, 12 and 24-month remission; (c) time to first seizure post randomization; (d) quality of life measures if available. Clinical heterogeneity was assessed by reviewing differences across trials

Full Text available with Trip Pro

2006 Cochrane

17. Oxcarbazepine

Oxcarbazepine Oxcarbazepine Oxcarbazepine Mitchell A Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Mitchell A. Oxcarbazepine. University HealthSystem Consortium (UHC). Drug Monograph. 2001 Authors' objectives The UHC Drug Monographs are a continuing series of authoritative, concise evaluations of new and emerging pharmaceuticals. Monographs are written by drug

2001 Health Technology Assessment (HTA) Database.